biotech-companies-seed-43.html
Novo Annual Report 2015
44 / 72
acesion
pharma
adenium biotech
affinicon avilex pharma biosyntia io biotech minervax pcovery reapplix denator galecto biotech glionova rspr pharma forendo pharma seed companies pre-seed projects antibiotx biofilm bioprotect dare diacure glyprovac immunitrack map1 mirana monta nmd pharma rsk inhibitors zentrix apoa-i derived peptides biopetrolia metabogen aa project jak2 pepticrad pluvia zinchel active seed companies and pre-seed projects lysogene inthera bioscience achievements in portfolio companies in 2015 biosyntia closed a dkk 12.5 million financing round with novo seeds as lead investor. biosyntia is one of the region?s emerging start-ups. the company
aims to deliver sustainable and biobased solutions, drawing on the extensive commercial experience and strong research based in denmark. galecto biotech started a phase 2a clinical trial for td139 treatment of patients with idiopathic pulmonary fibrosis in the uk. the company expects to complete this study during 2016. minervax observed strong antibody responses and good tolerability in the company?s on-going phase 1 clinical study of a vaccine against invasive group b streptococcus. io biotech tested the new and improved version of the company?s ido-targeted vaccine approach in melanoma cancer patients. rspr pharma completed their first clinical proof-of-concept studies. new pre-seed grants in 2015 apoa-i is exploring how to characterise short peptides and how to assess their potential as novel therapeutic agents. bioprotect is developing cell factories for production of biocides by fermentation. dare project has identified and investigated a novel target for the treatment of wet (advanced) amd, microfibrillar-associated protein 4 (mfap4). diacure is developing autologous stem cells for the treatment of type 1 diabetes. pepticrad has developed a novel technology for enhancing efficacy of oncolytic virotherapies. zinchel focuses on the development and characterisation of novel inhibitors of metallo-beta-lactamases (mbls). novo a/s 44 novo seeds
www-com-develops-45.html
